Global Clinical Trial Kits Market
Global Clinical Trial Kits Market (2022 to 2030) - Featuring Almac, Alpha Laboratories and Brooks Life Science Among Others
September 09, 2022 07:03 ET | Research and Markets
Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service , By Phase , By Region; Segment Forecast, 2022 - 2030" report has...
Global TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Billion by 2028, Driven by the First Drug Approval Expected to be Launched by 2024
August 08, 2022 06:33 ET | Research and Markets
Dublin, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to's offering. The global...
Global Clinical Trials Market
Global Clinical Trials Markets Report 2022: In 2020, IQVIA Dominated the Market, Followed by PPD, Syneos Health, PRA Health Sciences, and LabCorp - Forecast to 2026
March 28, 2022 04:13 ET | Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy...
AI Therapeutics Logo.jpg
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
January 13, 2022 10:38 ET | AI Therapeutics, Inc.
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
Shareholder Update Q3 2018
October 02, 2018 00:00 ET | Factor Therapeutics
Highlights: Venous leg ulcer Phase 2 trial on track:  top-line results mid-NovemberDiabetic foot ulcer pilot clinical study: in development with key US researchersOcular wounds: international patent...
Phase 2 Clinical Trial for Venous Leg Ulcers Nears Completion
September 05, 2018 20:00 ET | Factor Therapeutics
BRISBANE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is...
Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
August 20, 2018 08:19 ET | Taiwan Liposome Company, Ltd.
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through  Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...
Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds
December 20, 2016 09:00 ET | Factor Therapeutics
BRISBANE, Australia, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX:FTT) is pleased to announce that it has enrolled the first patient for its US multi-centre Phase II trial of...